Addex Therapeutics (NASDAQ:ADXN – Get Free Report) and Verona Pharma (NASDAQ:VRNA – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.
Profitability
This table compares Addex Therapeutics and Verona Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Addex Therapeutics | 850.30% | -112.43% | -77.95% |
| Verona Pharma | N/A | -79.54% | -43.49% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Addex Therapeutics and Verona Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Addex Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Verona Pharma | 0 | 0 | 6 | 0 | 3.00 |
Valuation & Earnings
This table compares Addex Therapeutics and Verona Pharma”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Addex Therapeutics | $556,045.00 | 15.96 | -$11.76 million | ($0.34) | -24.62 |
| Verona Pharma | $5.62 million | 666.38 | -$54.37 million | ($1.92) | -24.27 |
Addex Therapeutics has higher earnings, but lower revenue than Verona Pharma. Addex Therapeutics is trading at a lower price-to-earnings ratio than Verona Pharma, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Addex Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.
Institutional & Insider Ownership
16.1% of Addex Therapeutics shares are held by institutional investors. Comparatively, 85.9% of Verona Pharma shares are held by institutional investors. 15.0% of Addex Therapeutics shares are held by insiders. Comparatively, 4.8% of Verona Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Verona Pharma beats Addex Therapeutics on 7 of the 13 factors compared between the two stocks.
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
About Verona Pharma
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Addex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
